Literature DB >> 11866676

Economic aspects of medical erectile dysfunction therapies.

Aristotelis G Anastasiadis1, Mohamed A Ghafar, Martin Burchardt, Ridwan Shabsigh.   

Abstract

The introduction of safe and effective oral therapies has changed the significance of erectile dysfunction (ED) forever. Seldom has a new drug changed the landscape of pharmacotherapy in so many ways as sildenafil (Viagra, Pfizer). This article highlights the various oral, intracavernosal and intraurethral therapies currently available for ED and evaluates the socio-economic impact of each method.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11866676     DOI： 10.1517/14656566.3.3.257

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  3 in total

1.  Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: Results from a prospective real-world observational study in the United Kingdom.

Authors:  Lauren J Lee; Terence A Maguire; Martine C Maculaitis; Birol Emir; Vicky W Li; Mara Jeffress; Jim Z Li; Kelly H Zou; Shaantanu S Donde; David Taylor
Journal:  Int J Clin Pract       Date:  2020-12-05       Impact factor: 2.503

Review 2.  Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.

Authors:  Giovanni Vanni Frajese; Flavio Pozzi; Gaetano Frajese
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 3.  Current penile-rehabilitation strategies: Clinical evidence.

Authors:  Robert L Segal; Trinity J Bivalacqua; Arthur L Burnett
Journal:  Arab J Urol       Date:  2013-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.